Clinical Trial Update: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 intravenous infusion trial of the investigational agent rHIgM22 in patients with multiple sclerosis. The trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• rHIgM22 (rHIgM22)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED